市販薬（OTC）- 市場の洞察、疫学、市場予測：2030年

市販薬の市場規模は、2023年に1,511億5,000万米ドルとなりました。同市場は、2024年から2030年までの予測期間中にCAGR 5.93％で拡大し、2030年には2,130億8,000万米ドルに達すると予測されています。市販薬市場は、いくつかの相互関連的な要因によって力強い成長を遂げています。処方薬のOTC化が加速していることに加え、急性・慢性疼痛の発生につながる様々な健康状態の有病率が上昇していることが、市販薬市場を大きく押し上げています。この動向により、消費者は処方箋を必要とせず、より簡単かつ迅速に効果的な治療にアクセスできるようになり、セルフケアに対する需要の高まりに対応しています。さらに、世界中で規制当局の支援が広がっているため、再分類プロセスが促進され、安全で効果的なOTC薬の選択肢が確保されています。その結果、これらの要因が総合的に市販薬市場の拡大を後押しし、便利で手ごろな価格の、利用しやすい薬物療法の選択肢を求める消費者の進化するヘルスケアニーズや嗜好に応えています。したがって、2024年から2030年までの予測期間中、これらの要因が総合的に市販薬市場を押し上げることになります。

処方箋を必要とせず、薬局や小売店で手軽に購入できる市販薬のコンビニエンスストアは、迅速かつ効果的な疼痛管理ソリューションを求める関節炎患者にアピールし、市場を後押ししています。さらに、市販薬市場の成長を促進する主な要因の1つは、関節炎、腰痛、線維筋痛症などの問題の原因となる筋骨格系に影響を与える様々な様式の増加による鎮痛薬の使用の急増であり、生理痛、頭痛などの他の適応症も含まれます。

さらに、風邪、咳、アレルギー、胃腸の問題などの一般的な病気の有病率の上昇が、市販薬の需要を押し上げています。季節的な変化や環境的な要因も、こうした製品の繰り返し必要とされる要因となっています。

しかし、副作用やアレルギー反応に加え、ヘルスケア専門家による適切な指導を受けずに誤用・過剰使用したり、消費者が誤った用法・用量を服用したり、市販薬を推奨期間より長く使用したり、他の医薬品と不適切に併用したりして、副作用や薬物相互作用につながることが、予測期間中の市販薬の成長を妨げる可能性があります。

当レポートでは、世界の市販薬（OTC）市場について調査し、市場の概要とともに、治療薬分野別、剤形別、流通チャネル別、地域別動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 市販薬市場レポートのイントロダクション

第2章 市販薬市場のエグゼクティブサマリー

第3章 競合情勢

第4章 規制分析

• 米国
• 欧州
• 日本
• 中国

第5章 市販薬市場の主な要因分析

• 市販薬市場の促進要因
• 市販薬市場の抑制要因と課題
• 市販薬市場の機会

第6章 市販薬市場におけるポーターのファイブフォース分析

第7章 市販薬市場の評価

• 治療分野別
• 剤形別
• 流通チャネル別
• 地域別

第8章 市販薬市場の企業と製品のプロファイル

• Johnson & Johsnon Services Inc.
• BAYER AG
• Novartis
• Sanofi-aventis U.S. LLC.
• Pfizer Inc.
• GlaxoSmithKline plc.
• Cipla Inc.
• Piramal Enterprises Limited
• Duramed Pharmaceuticals, Inc.
• Glenmark Pharmaceuticals
• Dr. Reddy's Laboratories
• Innovus Pharmaceuticals, Inc.
• Teva Pharmaceutical Industries Ltd.
• Viatris Inc.
• Reckitt Benckiser Group PLC
• Afaxys Pharma LLC
• FOUNDATION CONSUMER HEALTHCARE
• Alcon Inc.
• Teva Pharmaceutical Industries
• Sun Pharmaceutical Industries Ltd.

第9章 KOLの見解

第10章 プロジェクトのアプローチ

第11章 DelveInsightについて

第12章 免責事項とお問い合わせ

List of Tables

• Table 1: Competitive Analysis
• Table 2: Over-the-Counter Drugs Market in Global (2021-2030)
• Table 3: Over-the-Counter Drugs Market in Global by Therapeutics (2021-2030)
• Table 4: Over-the-Counter Drugs Market in Global by Formulation (2021-2030)
• Table 5: Over-the-Counter Drugs Market in Global by Distribution Channel (2021-2030)
• Table 6: Over-the-Counter Drugs Market in Global by Geography (2021-2030)
• Table 7: Over-the-Counter Drugs Market in North America (2021-2030)
• Table 8: Over-the-Counter Drugs Market in the United States (2021-2030)
• Table 9: Over-the-Counter Drugs Market in Canada (2021-2030)
• Table 10: Over-the-Counter Drugs Market in Mexico (2021-2030)
• Table 11: Over-the-Counter Drugs Market in Europe (2021-2030)
• Table 12: Over-the-Counter Drugs Market in France (2021-2030)
• Table 13: Over-the-Counter Drugs Market in Germany (2021-2030)
• Table 14: Over-the-Counter Drugs Market in United Kingdom (2021-2030)
• Table 15: Over-the-Counter Drugs Market in Italy (2021-2030)
• Table 16: Over-the-Counter Drugs Market in Spain (2021-2030)
• Table 17: Over-the-Counter Drugs Market in the Rest of Europe (2021-2030)
• Table 18: Over-the-Counter Drugs Market in Asia-Pacific (2021-2030)
• Table 19: Over-the-Counter Drugs Market in China (2021-2030)
• Table 20: Over-the-Counter Drugs Market in Japan (2021-2030)
• Table 21: Over-the-Counter Drugs Market in India (2021-2030)
• Table 22: Over-the-Counter Drugs Market in Australia (2021-2030)
• Table 23: Over-the-Counter Drugs Market in South Korea (2021-2030)
• Table 24: Over-the-Counter Drugs Market in Rest of Asia-Pacific (2021-2030)
• Table 25: Over-the-Counter Drugs Market in the Rest of the World (2021-2030)
• Table 26: Over-the-Counter Drugs Market in the Middle East (2021-2030)
• Table 27: Over-the-Counter Drugs Market in Africa (2021-2030)
• Table 28: Over-the-Counter Drugs Market in South America (2021-2030)

List of Figures

• Figure 1: Competitive Analysis
• Figure 2: Over-the-Counter Drugs Market in Global (2021-2030)
• Figure 3: Over-the-Counter Drugs Market in Global by Therapeutics (2021-2030)
• Figure 4: Over-the-Counter Drugs Market in Global by Formulation (2021-2030)
• Figure 5: Over-the-Counter Drugs Market in Global by Distribution Channel (2021-2030)
• Figure 6: Over-the-Counter Drugs Market in Global by Geography (2021-2030)
• Figure 7: Over-the-Counter Drugs Market in North America (2021-2030)
• Figure 8: Over-the-Counter Drugs Market in the United States (2021-2030)
• Figure 9: Over-the-Counter Drugs Market in Canada (2021-2030)
• Figure 10: Over-the-Counter Drugs Market in Mexico (2021-2030)
• Figure 11: Over-the-Counter Drugs Market in Europe (2021-2030)
• Figure 12: Over-the-Counter Drugs Market in France (2021-2030)
• Figure 13: Over-the-Counter Drugs Market in Germany (2021-2030)
• Figure 14: Over-the-Counter Drugs Market in United Kingdom (2021-2030)
• Figure 15: Over-the-Counter Drugs Market in Italy (2021-2030)
• Figure 16: Over-the-Counter Drugs Market in Spain (2021-2030)
• Figure 17: Over-the-Counter Drugs Market in the Rest of Europe (2021-2030)
• Figure 18: Over-the-Counter Drugs Market in Asia-Pacific (2021-2030)
• Figure 19: Over-the-Counter Drugs Market in China (2021-2030)
• Figure 20: Over-the-Counter Drugs Market in Japan (2021-2030)
• Figure 21: Over-the-Counter Drugs Market in India (2021-2030)
• Figure 22: Over-the-Counter Drugs Market in Australia (2021-2030)
• Figure 23: Over-the-Counter Drugs Market in South Korea (2021-2030)
• Figure 24: Over-the-Counter Drugs Market in Rest of Asia-Pacific (2021-2030)
• Figure 25: Over-the-Counter Drugs Market in the Rest of the World (2021-2030)
• Figure 26: Over-the-Counter Drugs Market in the Middle East (2021-2030)
• Figure 27: Over-the-Counter Drugs Market in Africa (2021-2030)
• Figure 28: Over-the-Counter Drugs Market in South America (2021-2030)
• Figure 29: Market Drivers
• Figure 30: Market Barriers
• Figure 31: Market Opportunities
• Figure 32: PORTER'S Five Force Analysis

Over-the-Counter Drugs Market by Therapeutics (Cough, Cold & Allergy, Gastrointestinal, Analgesics, Dermatological, and Others), Formulation (Tablets, Powders & Capsules, Drops, Topical Creams & Ointments, and Others), Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2030 owing to the increasing expedited conversion of prescription medications to OTC status, increasing prevalence of various indications resulting in incidents of acute and chronic pains leading to extensive use of OTC drugs, and regulatory support across the globe.

The over-the-counter drugs market was valued at USD 151.15 billion in 2023, growing at a CAGR of 5.93% during the forecast period from 2024 to 2030 to reach USD 213.08 billion by 2030. The market for over-the-counter drugs is experiencing robust growth driven by several interconnected factors. The increasing expedited conversion of prescription medications to OTC status, combined with the rising prevalence of various health conditions leading to incidents of acute and chronic pain, significantly boosts the market for over-the-counter drugs. This trend allows consumers to access effective treatments more easily and quickly without the need for a prescription, catering to the growing demand for self-care solutions. Additionally, widespread regulatory support across the globe facilitates the reclassification process and ensures the availability of safe and effective OTC options. As a result, these factors collectively drive the expansion of the OTC drug market, meeting the evolving healthcare needs and preferences of consumers seeking convenient, affordable, and accessible medication options. Thus, these factors collectively boost the over-the-counter drugs market, during the forecast period from 2024 to 2030.

Over-the-Counter Drugs Market Dynamics:

According to a recent study published under the Global Burden of Disease (2023), nearly 1 billion people were projected to be living with osteoarthritis, the most common form of arthritis, by 2050. Currently, 15% of individuals aged 30 and older experience osteoarthritis. The most common sites for osteoarthritis are the knees and hands. By 2050, cases of osteoarthritis of the knee are expected to increase by 75%, while cases of osteoarthritis of the hand are anticipated to rise by 50%. Additionally, as per the recent update provided by the Australian Bureau of Statistics (2023), in 2022, under 3.7 million (14.5%) people had arthritis. For individuals aged 45-54 years, the proportion is almost seven times higher than for those aged 0-44 years (16.2% compared to 2.5%). The prevalence almost doubled between the ages of 45-54 years and 55-64 years (16.2% compared to 30.5%). Older adults aged 75 years and over were more likely than any other age group to have arthritis, with almost one in two (48.9%) having the condition in 2022. As arthritis commonly results in chronic pain and inflammation, affected individuals often seek immediate and accessible relief. OTC medications such as nonsteroidal anti-inflammatory drugs (NSAIDs), acetaminophen, and topical analgesics are widely used to manage arthritis symptoms. The convenience of OTC drugs, which do not require a prescription and can be readily purchased from pharmacies and retail stores, appeals to arthritis sufferers looking for quick and effective pain management solutions thereby boosting the market. Additionally, one of the primary factors driving the over-the-counter drugs market growth is the upsurge in the use of analgesics due to an increase in various modalities affecting the musculoskeletal system causing problems such as arthritis, back pain, and fibromyalgia among other indications such as menstrual cramps, headaches etcetera.

Another prominent factor responsible for the increasing demand for OTC drugs is the upsurge in cases of unintended pregnancies across the globe, which is expected to influence the demand for over-the-counter emergency contraception pills during the forecast period. According to the recent data provided by the United Nations Fund for Population Activities (UNFPA) (2022), approximately 121 million pregnancies each year worldwide were unintended, affecting nearly half of all women and girls. For these individuals, the pivotal reproductive decision of whether to conceive or not was frequently beyond their control. Therefore, when unintended pregnancies occur, there is an increased demand for emergency contraception, such as the morning-after pill, which is available OTC. This immediate need for accessible, effective contraception drives higher sales of these products. Additionally, product approvals through regulatory bodies have also contributed to escalating the market of over-the-counter contraceptive drugs across the region. For instance, in July 2023, the FDA approved the first nonprescription daily oral contraceptive, a progestin-only pill, Opill, enabling consumers to buy the OTC contraceptive without a prescription. This approval allows the pill to be sold at drug stores, convenience stores, grocery stores, and online. Thus, allowing the purchase of progestin-only pills without a prescription may eliminate barriers to obtaining contraceptive medicine, particularly for those who may face difficulties in accessing healthcare providers thereby boosting the overall market of over-the-counter drugs.

Additionally, the increasing prevalence of common ailments such as colds, coughs, allergies, and gastrointestinal issues drives the demand for OTC drugs. Seasonal changes and environmental factors contribute to the recurring need for these products.

However, the side effects and allergic reactions along with misuse and overuse without the proper guidance from healthcare professionals, consumers might take incorrect dosages, use OTC drugs for longer than recommended, or combine them with other medications inappropriately, leading to adverse effects or drug interactions may hinder the growth of over-the-counter drugs during the forecast period.

Over-the-Counter Drugs Market Segment Analysis:

Over-the-Counter Drugs Market by Therapeutic Category (Cough, Cold & Allergy, Gastrointestinal, Analgesics, Dermatological, and Others), Formulation (Tablets, Powders & Capsules, Drops, Topical Creams & Ointments, and Others), Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the therapeutic segment of the over-the-counter drugs market, the cold & allergy category is estimated to have a significant revenue share in the anti-infective drug market in 2023. Cold and allergy conditions significantly boost the overall market for over-the-counter (OTC) drugs, serving as dominant factors due to their high prevalence and recurrent nature. Colds are among the most common illnesses worldwide, affecting millions of individuals annually. Allergic reactions to pollen, dust, pet dander, and other allergens lead to symptoms like sneezing, itching, runny nose, and watery eyes. The chronic and often unpredictable nature of allergies causes sufferers to frequently purchase OTC remedies such as antihistamines, nasal sprays, and eye drops.

Additionally, the increasing cases of colds and allergies have further propelled the market for over-the-counter drugs. According, to the recent data provided by the Centre for Disease Control and Prevention (2023), in 2021, nearly 1 in 3 U.S. adults and more than 1 in 4 U.S. children reported having a seasonal allergy, eczema, or food allergy. About 25.7% of adults have a seasonal allergy, 7.3% have eczema, and 6.2% have a food allergy. As the cases of cold and allergy rise, there is a substantial and continuous demand for effective and accessible treatments. OTC medications such as antihistamines, decongestants, topical creams, and other allergy relief products are essential for managing the symptoms associated with these conditions thereby boosting the overall market of over-the-counter drugs.

Additionally, the segment acts as a boosting factor in escalating the overall market of over-the-counter drugs due to several regulatory approvals of OTC medication. For instance, in March 2022, the FDA approved Nasonex which provides temporary relief to hay fever or other upper respiratory allergies: nasal congestion, runny nose, sneezing, and itchy nose.

Thus, the above-mentioned factors are expected to boost the overall market of OTC medication during the forecast period.

North America is expected to dominate the overall over-the-counter drugs market:

North America is expected to account for the highest proportion of the over-the-counter drugs market in 2023, out of all regions. This can be ascribed to the increasing number of switches from prescription drugs to OTC status for various drugs, increase in chronic pain, increasing prevalence of common ailments such as colds, coughs, allergies, and gastrointestinal issues, increase in regulatory approval of over-the-counter drugs across the globe, and the presence of key market players in the region driving the over-the-counter drugs market in North America.

As per the Allergy and Asthma Foundation of America (2021), allergies are the sixth leading cause of chronic illness in the United States. The source further mentioned that over 50 million Americans experience various types of allergies each year. Additionally, as per Food Allergy and Education (2022), 32 million people have food allergies across the country. This widespread prevalence creates a substantial and continuous need for effective allergy management solutions thereby boosting the market of over-the-counter drugs.

As per the recent data provided by the Centre for Disease Control and Prevention (CDC) (2023), from 2019 to 2021, statistics revealed that about 21.2% of adults in the United States, totaling approximately 53.2 million individuals, were diagnosed with arthritis by a healthcare professional. Among these, women experienced a higher prevalence, with 20.9% affected, compared to 16.3% of men. Moreover, veterans exhibited a higher prevalence of arthritis at 24.2%, surpassing the 18.5% prevalence rate among non-veterans. Additionally, the likelihood of being diagnosed with arthritis increases with age. These conditions often lead to severe joint pain, deformities, and loss of function, necessitating over-the-counter drugs such as Acetaminophen, Ibuprofen, Naproxen, and others thereby boosting the future market in the United States.

Additionally, the extensive switch of the Rx medication to OTC status is another factor driving the market growth in the North American region. For instance, in March 2022, Nasonex 24HR Allergy (mometasone furoate) nasal spray was given OTC status by the US FDA.

Therefore, the interplay of the aforementioned factors above would provide a conducive growth environment for the North American region in the over-the-counter drugs market.

Over-the-Counter Drugs Market Key Players:

Some of the key market players operating in the over-the-counter drugs market include Johnson & Johsnon Services Inc., BAYER AG, Novartis, Sanofi-aventis U.S. LLC., Pfizer Inc., GlaxoSmithKline plc., Cipla Inc., Piramal Enterprises Limited, Duramed Pharmaceuticals, Inc., Glenmark Pharmaceuticals, Dr. Reddy's Laboratories, Innovus Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., Viatris Inc, Reckitt Benckiser Group PLC, Afaxys Pharma, LLC, FOUNDATION CONSUMER HEALTHCARE, Alcon Inc., Teva Pharmaceutical Industries, Sun Pharmaceutical Industries Ltd., and others.

Recent Developmental Activities in the Over-the-Counter Drugs Market:

• In March 2023, the U.S. Food and Drug Administration approved Narcan, a nasal spray that is used in the treatment of known or suspected opioid overdose.
• In December 2021, the US Food and Drug Administration approved the prescription drug Lastacaft (alcaftadine ophthalmic solution), 0.25% to an over-the-counter drug.
• In June 2021, Bayer received regulatory approval from the US FDA for their product Asepro Allergy as an OTC drug for temporary relief from nasal congestion, itch and runny nose, and other respiratory allergies.

Key takeaways from the over-the-counter drugs market report study:

• Market size analysis for current over-the-counter drugs size (2023), and market forecast for 6 years (2024 to 2030)
• Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years
• Key companies dominating the over-the-counter drugs market.
• Various opportunities available for the other competitors in the over-the-counter drugs market space.
• What are the top-performing segments in 2023? How these segments will perform in 2030?
• Which are the top-performing regions and countries in the current over-the-counter drugs market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for over-the-counter drugs market growth in the coming future?

Target audience who can be benefited from this over-the-counter drugs market report study:

• Over-the-counter drugs providers
• Research organizations and consulting companies
• Over-the-counter drugs related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and traders dealing in over-the-counter drugs
• Various end-users who want to know more about the over-the-counter drugs market and the latest technological developments in the over-the-counter drugs market.

Frequently Asked Questions for the Over-the-Counter Drugs Market:

1. What are over-the-counter drugs?

Over-the-counter (OTC) drugs are medications that can be purchased without a prescription from a healthcare professional. These drugs are considered safe and effective for use by the general public when used according to the directions on the label. OTC drugs are commonly used to treat a variety of health issues, such as pain, fever, cough, cold, allergies, digestive problems, and minor infections.

2. What is the market for over-the-counter drugs?

The over-the-counter drugs market was valued at USD 151.15 billion in 2023, growing at a CAGR of 5.93% during the forecast period from 2024 to 2030 to reach USD 213.08 billion by 2030.

3. What are the drivers for the over-the-counter drugs market?

The market for over-the-counter drugs is experiencing robust growth driven by several interconnected factors. The increasing expedited conversion of prescription medications to OTC status, combined with the rising prevalence of various health conditions leading to incidents of acute and chronic pain, significantly boosts the market for over-the-counter drugs. This trend allows consumers to access effective treatments more easily and quickly without the need for a prescription, catering to the growing demand for self-care solutions. Additionally, widespread regulatory support across the globe facilitates the reclassification process and ensures the availability of safe and effective OTC options. As a result, these factors collectively drive the expansion of the OTC drug market, meeting the evolving healthcare needs and preferences of consumers seeking convenient, affordable, and accessible medication options. Thus, these factors collectively boost the over-the-counter drugs market, during the forecast period from 2024 to 2030.

4. Who are the key players operating in the over-the-counter drugs market?

Some of the key market players operating in the Over-the-Counter Drugs are Johnson & Johsnon Services Inc., BAYER AG, Novartis, Sanofi-aventis U.S. LLC., Pfizer Inc., GlaxoSmithKline plc., Cipla Inc., Piramal Enterprises Limited, Duramed Pharmaceuticals, Inc., Glenmark Pharmaceuticals, Dr. Reddy's Laboratories, Innovus Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., Viatris Inc, Reckitt Benckiser Group PLC, Afaxys Pharma, LLC, FOUNDATION CONSUMER HEALTHCARE, Alcon Inc., Teva Pharmaceutical Industries, Sun Pharmaceutical Industries Ltd., and others.

5. Which region has the highest share in the over-the-counter drugs market?

North America is expected to account for the highest proportion of the over-the-counter drugs market in 2023, out of all regions. This can be ascribed to the increasing number of switches from prescription drugs to OTC status for various drugs, increase in chronic pain, increasing prevalence of common ailments such as colds, coughs, allergies, and gastrointestinal issues, increase in regulatory approval of over-the-counter drugs across the globe, and the presence of key market players in the region driving the over-the-counter drugs market in North America.

Table of Contents

1. Over-the-Counter Drugs Market Report Introduction

• 1.1. Scope of the Study
• 1.2. Market Segmentation
• 1.3. Market Assumption

2. Over-the-Counter Drugs Market Executive Summary

• 2.1. Market at Glance

3. Competitive Landscape

4. Regulatory Analysis

• 4.1. The United States
• 4.2. Europe
• 4.3. Japan
• 4.4. China

5. Over-the-Counter Drugs Market Key Factors Analysis

• 5.1. Over-the-Counter Drugs Market Drivers
  • 5.1.1. The increasing expedited conversion of prescription medications to OTC status
  • 5.1.2. Increasing prevalence of various indications resulting in incidents of acute and chronic pains leading to extensive use of OTC drugs
  • 5.1.3. Increase in regulatory support across the globe.
• 5.2. Over-the-Counter Drugs Market Restraints and Challenges
  • 5.2.1. The side effects and allergic reactions due to the use of OTC drugs
  • 5.2.2. The misuse and overuse of OTC drugs without the proper guidance from healthcare professionals lead to adverse effects
• 5.3. Over-the-Counter Drugs Market Opportunities
  • 5.3.1. Widening the supply chain network in emerging economies

6. Over-the-Counter Drugs Market Porter's Five Forces Analysis

• 6.1. Bargaining Power of Suppliers
• 6.2. Bargaining Power of Consumers
• 6.3. Threat of New Entrants
• 6.4. Threat of Substitutes
• 6.5. Competitive Rivalry

7. Over-the-Counter Drugs Market Assessment

• 7.1. By Therapeutics
  • 7.1.1. Cough
  • 7.1.2. Cold & Allergy
  • 7.1.3. Gastrointestinal
  • 7.1.4. Analgesics
  • 7.1.5. Dermatological
  • 7.1.6. Others
• 7.2. By Formulation
  • 7.2.1. Tablets
  • 7.2.2. Powder & Capsules
  • 7.2.3. Drops
  • 7.2.4. Topical Creams & Ointments
  • 7.2.5. Others
• 7.3. Distribution Channel
  • 7.3.1. Hospitals Pharmacy
  • 7.3.2. Retail Pharmacy
  • 7.3.3. Online Pharmacy
  • 7.3.4. Others
• 7.4. By Geography
  • 7.4.1. North America
    • 7.4.1.1. United States Over-the-Counter Drugs Market Size in USD Million (2021-2030)
    • 7.4.1.2. Canada Over-the-Counter Drugs Market Size in USD Million (2021-2030)
    • 7.4.1.3. Mexico Over-the-Counter Drugs Market Size in USD Million (2021-2030)
  • 7.4.2. Europe
    • 7.4.2.1. France Over-the-Counter Drugs Market Size in USD Million (2021-2030)
    • 7.4.2.2. Germany Over-the-Counter Drugs Market Size in USD Million (2021-2030)
    • 7.4.2.3. United Kingdom Over-the-Counter Drugs Market Size in USD Million (2021-2030)
    • 7.4.2.4. Italy Over-the-Counter Drugs Market Size in USD Million (2021-2030)
    • 7.4.2.5. Spain Over-the-Counter Drugs Market Size in USD Million (2021-2030)
    • 7.4.2.6. Rest of Europe Over-the-Counter Drugs Market Size in USD Million (2021-2030)
  • 7.4.3. Asia-Pacific
    • 7.4.3.1. China Over-the-Counter Drugs Market Size in USD Million (2021-2030)
    • 7.4.3.2. Japan Over-the-Counter Drugs Market Size in USD Million (2021-2030)
    • 7.4.3.3. India Over-the-Counter Drugs Market Size in USD Million (2021-2030)
    • 7.4.3.4. Australia Over-the-Counter Drugs Market Size in USD Million (2021-2030)
    • 7.4.3.5. South Korea Over-the-Counter Drugs Market Size in USD Million (2021-2030)
    • 7.4.3.6. Rest of Asia-Pacific Over-the-Counter Drugs Market Size in USD Million (2021-2030)
  • 7.4.4. Rest of the World (RoW)
    • 7.4.4.1. Middle East Over-the-Counter Drugs Market Size in USD Million (2021-2030)
    • 7.4.4.2. Africa Over-the-Counter Drugs Market Size in USD Million (2021-2030)
    • 7.4.4.3. South America Over-the-Counter Drugs Market Size in USD Million (2021-2030)

8. Over-the-Counter Drugs Market Company and Product Profiles

• 8.1. Johnson & Johsnon Services Inc.
  • 8.1.1. Company Overview
  • 8.1.2. Company Snapshot
  • 8.1.3. Financial Overview
  • 8.1.4. Product Listing
  • 8.1.5. Entropy
• 8.2. BAYER AG
  • 8.2.1. Company Overview
  • 8.2.2. Company Snapshot
  • 8.2.3. Financial Overview
  • 8.2.4. Product Listing
  • 8.2.5. Entropy
• 8.3. Novartis
  • 8.3.1. Company Overview
  • 8.3.2. Company Snapshot
  • 8.3.3. Financial Overview
  • 8.3.4. Product Listing
  • 8.3.5. Entropy
• 8.4. Sanofi-aventis U.S. LLC.
  • 8.4.1. Company Overview
  • 8.4.2. Company Snapshot
  • 8.4.3. Financial Overview
  • 8.4.4. Product Listing
  • 8.4.5. Entropy
• 8.5. Pfizer Inc.
  • 8.5.1. Company Overview
  • 8.5.2. Company Snapshot
  • 8.5.3. Financial Overview
  • 8.5.4. Product Listing
  • 8.5.5. Entropy
• 8.6. GlaxoSmithKline plc.
  • 8.6.1. Company Overview
  • 8.6.2. Company Snapshot
  • 8.6.3. Financial Overview
  • 8.6.4. Product Listing
  • 8.6.5. Entropy
• 8.7. Cipla Inc.
  • 8.7.1. Company Overview
  • 8.7.2. Company Snapshot
  • 8.7.3. Financial Overview
  • 8.7.4. Product Listing
  • 8.7.5. Entropy
• 8.8. Piramal Enterprises Limited
  • 8.8.1. Company Overview
  • 8.8.2. Company Snapshot
  • 8.8.3. Financial Overview
  • 8.8.4. Product Listing
  • 8.8.5. Entropy
• 8.9. Duramed Pharmaceuticals, Inc.
  • 8.9.1. Company Overview
  • 8.9.2. Company Snapshot
  • 8.9.3. Financial Overview
  • 8.9.4. Product Listing
  • 8.9.5. Entropy
• 8.10. Glenmark Pharmaceuticals
  • 8.10.1. Company Overview
  • 8.10.2. Company Snapshot
  • 8.10.3. Financial Overview
  • 8.10.4. Product Listing
  • 8.10.5. Entropy
• 8.11. Dr. Reddy's Laboratories
  • 8.11.1. Company Overview
  • 8.11.2. Company Snapshot
  • 8.11.3. Financial Overview
  • 8.11.4. Product Listing
  • 8.11.5. Entropy
• 8.12. Innovus Pharmaceuticals, Inc.
  • 8.12.1. Company Overview
  • 8.12.2. Company Snapshot
  • 8.12.3. Financial Overview
  • 8.12.4. Product Listing
  • 8.12.5. Entropy
• 8.13. Teva Pharmaceutical Industries Ltd.
  • 8.13.1. Company Overview
  • 8.13.2. Company Snapshot
  • 8.13.3. Financial Overview
  • 8.13.4. Product Listing
  • 8.13.5. Entropy
• 8.14. Viatris Inc.
  • 8.14.1. Company Overview
  • 8.14.2. Company Snapshot
  • 8.14.3. Financial Overview
  • 8.14.4. Product Listing
  • 8.14.5. Entropy
• 8.15. Reckitt Benckiser Group PLC
  • 8.15.1. Company Overview
  • 8.15.2. Company Snapshot
  • 8.15.3. Financial Overview
  • 8.15.4. Product Listing
  • 8.15.5. Entropy
• 8.16. Afaxys Pharma LLC
  • 8.16.1. Company Overview
  • 8.16.2. Company Snapshot
  • 8.16.3. Financial Overview
  • 8.16.4. Product Listing
  • 8.16.5. Entropy
• 8.17. FOUNDATION CONSUMER HEALTHCARE
  • 8.17.1. Company Overview
  • 8.17.2. Company Snapshot
  • 8.17.3. Financial Overview
  • 8.17.4. Product Listing
  • 8.17.5. Entropy
• 8.18. Alcon Inc.
  • 8.18.1. Company Overview
  • 8.18.2. Company Snapshot
  • 8.18.3. Financial Overview
  • 8.18.4. Product Listing
  • 8.18.5. Entropy
• 8.19. Teva Pharmaceutical Industries
  • 8.19.1. Company Overview
  • 8.19.2. Company Snapshot
  • 8.19.3. Financial Overview
  • 8.19.4. Product Listing
  • 8.19.5. Entropy
• 8.20. Sun Pharmaceutical Industries Ltd.
  • 8.20.1. Company Overview
  • 8.20.2. Company Snapshot
  • 8.20.3. Financial Overview
  • 8.20.4. Product Listing
  • 8.20.5. Entropy

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us